Merck will present PCSK9 inhibitor data at AHA 2025.

Rahway, N.J., October 23, 2025 – Merck (NYSE: MRK) announced that it will present new data from the company’s cardiopulmonary portfolio and research pipeline at the American Heart Association (AHA) Scientific Sessions 2025, taking place in New Orleans, Louisiana from November 7 to 10, 2025.

The data to be presented at AHA underscores the ongoing research in the fields of hypercholesterolemia and pulmonary arterial hypertension (PAH) with new evidence. These findings are considered an important step towards reducing the global burden of serious cardiovascular (CV) diseases.

Among the presentations, detailed data will be shared for the first time from the CORALreef Lipids study. This study is the largest to evaluate the safety and efficacy of the oral PCSK9 inhibitor enlicitide decanoate in adults with hypercholesterolemia and a significant history of atherosclerotic cardiovascular disease (ASCVD).

Other important presentations will include results from the CORALreef HeFH study. This study evaluated the safety and efficacy of the enlicitide sequence in adults with heterozygous familial hypercholesterolemia (HeFH). Additionally, an analysis of mortality and major morbidity outcomes associated with treatment using WINREVAIR™ (sotatercept-csrk) in adults with PAH will also be presented.

Dr. Joerg Koglin, Senior Vice President responsible for general and specialty areas at Merck Research Laboratories, noted that AHA is an important moment, stating, "Clinical specialists will see clinical trial results for the first time and discover the potential benefits of an oral PCSK9 inhibitor in addressing the burden of hypercholesterolemia."

Merck will also host an Investor Event concurrently with the AHA Scientific Sessions on November 9, 2025, at 6:00 PM CT. This event will provide information about the company’s cardiopulmonary strategy and program. The event will be accessible via live stream for investors and media representatives.

Merck has long focused on cardiovascular diseases and conducts effective research on the prevention and treatment of heart diseases worldwide. The enlicitide decanoate, developed as a PCSK9 inhibitor, is designed in a daily tablet form to lower LDL cholesterol and has the potential to be the first FDA-approved oral PCSK9 inhibitor.